Cargando…
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
Modulation of intracellular protein–protein interactions has been – and remains – a challenging goal for the discovery and development of small-molecule therapeutic agents. Progress in the pharmacological targeting and understanding at the molecular level of one such interaction that is relevant to...
Autor principal: | Fischer, Peter M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Kluwer Academic Publishers
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710987/ https://www.ncbi.nlm.nih.gov/pubmed/19617922 http://dx.doi.org/10.1007/s10989-006-9016-5 |
Ejemplares similares
-
Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
por: Plante, Jeffrey P., et al.
Publicado: (2009) -
Activity‐Directed Synthesis of Inhibitors of the p53/hDM2 Protein–Protein Interaction
por: Green, Adam I., et al.
Publicado: (2020) -
Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds
por: Liu, Li-Juan, et al.
Publicado: (2016) -
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2()
por: Dickens, Michael P., et al.
Publicado: (2013) -
Characterization and Molecular Mechanism of Peptide-Conjugated Gold Nanoparticle Inhibiting p53-HDM2 Interaction in Retinoblastoma
por: Kalmodia, Sushma, et al.
Publicado: (2017)